These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 13832156)

  • 1. The pharmacological actions of 3,4-dihydroxyphenyl-alpha-methylalanine (alpha-methyldopa), an inhibitor of 5-hydroxytryptophan decarboxylase.
    SMITH SE
    Br J Pharmacol Chemother; 1960 Jun; 15(2):319-27. PubMed ID: 13832156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of potential histidine decarboxylase inhibitors.
    MACKAY D; SHEPHERD DM
    Br J Pharmacol Chemother; 1960 Dec; 15(4):552-6. PubMed ID: 13764874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [5-HYDROXYTRYPTOPHAN DOPA DECARBOXYLASE IN NERVOUS AND CARDIAC TISSUES IN THE MOLLUSC HELIX POMATIA. INTERACTION OF SUBSTRATES IN VITRO].
    CARDOT J
    C R Hebd Seances Acad Sci; 1964 Jul; 259():902-4. PubMed ID: 14190531
    [No Abstract]   [Full Text] [Related]  

  • 4. [THE ROLE OF CATECHOLAMINES IN THE CONTROL OF HYPOTHALAMIC NEUROSECRETION. EFFECTS OF RESERPINE COMPOUNDS, MONOAMINE OXIDASE INHIBITORS AND D-1 DOPA 5-HTP DECARBOXYLASE INHIBITORS].
    CAHN J; HEROLD M
    Agressologie; 1964; 5():451-63. PubMed ID: 14192331
    [No Abstract]   [Full Text] [Related]  

  • 5. INFLUENCE OF METHYLDOPA ON CENTRAL EFFECTS OF RESERPINE.
    BENFEY BG; VARMA DR
    Br J Pharmacol Chemother; 1964 Apr; 22(2):366-70. PubMed ID: 14190471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homologs of dopa, alpha-methyldopa, and dopamine as potential cardiovascular drugs.
    Winn M; Rasmussen R; Minard F; Kyncl J; Plotnikoff N
    J Med Chem; 1975 Apr; 18(4):434-7. PubMed ID: 1079053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for a neurotransmitter role for 5-hydroxytryptamine in chick retina.
    Parkinson D; Rando RR
    J Neurosci; 1981 Nov; 1(11):1211-7. PubMed ID: 6118400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NTP Toxicology and Carcinogenesis Studies of alpha-Methyldopa Sesquihydrate (CAS No. 41372-08-1) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1989 Mar; 348():1-184. PubMed ID: 12704436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L- -methyl- -hydrazino- -(3,4-dihydroxyphenyl)propionic acid: relative lack of antidecarboxylase activity in adrenals.
    Horita A; Nair X; Hamilton AE
    Science; 1972 May; 176(4037):931-2. PubMed ID: 4537521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
    Alachkar A; Brotchie JM; Jones OT
    Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ENHANCEMENT BY RESERPINE AND ALPHA-METHYL DOPA OF THE EFFECTS OF D-AMPHETAMINE UPON THE LOCOMOTOR ACTIVITY OF MICE.
    SMITH CB
    J Pharmacol Exp Ther; 1963 Dec; 142():343-50. PubMed ID: 14098331
    [No Abstract]   [Full Text] [Related]  

  • 12. Decarboxylase inhibitors affect convulsion thresholds to hexafluorodiethyl ether.
    TRUITT EB; EBERSBERGER EM
    Science; 1962 Jan; 135(3498):105-6. PubMed ID: 13922689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microanalytical procedures for fluorometric assay of brain DOPA-5HTP decarboxylase, norepinephrine and serotonin, and a detailed mapping of decarboxylase activity in brain.
    KUNTZMAN R; SHORE PA; BOGDANSKI D; BRODIE BB
    J Neurochem; 1961 Feb; 6():226-32. PubMed ID: 13755185
    [No Abstract]   [Full Text] [Related]  

  • 14. [ACTION OF 5-HTP/DOPA DECARBOXYLASE INHIBITORS ON DIURESIS, URINARY ELECTROLYTES AND RELEASE OF THE ANTIDIURETIC HORMONE].
    CAHN J; HEROLD M; BARRE N
    C R Seances Soc Biol Fil; 1964; 158():1331-5. PubMed ID: 14210566
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacodynamics and clinical use of guanethidine, bretylium and methyldopa.
    KIRKENDALL WM; WILSON WR
    Am J Cardiol; 1962 Jan; 9():107-15. PubMed ID: 14456308
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparison of the effects of reversible and irreversible inhibitors of aromatic L-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3,4-dihydroxyphenylalanine.
    Huebert ND; Palfreyman MG; Haegele KD
    Drug Metab Dispos; 1983; 11(3):195-200. PubMed ID: 6135575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Hydroxytryptamine levels in brain of mice pretreated with Alpha-methyl-dopa.
    LEROY JG
    Arch Int Pharmacodyn Ther; 1961 Dec; 134():492-6. PubMed ID: 14464270
    [No Abstract]   [Full Text] [Related]  

  • 18. EFFECT OF SOME BENZYLHYDRAZINES AND BENZYLOXYAMINES ON DOPA AND 5-HYDROXYTRYPTOPHAN DECARBOXYLASE IN VIVO.
    HANSSON E; FLEMING RM; CLARK WG
    Int J Neuropharmacol; 1964 May; 3():177-88. PubMed ID: 14336525
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of alpha-methyldopa on the metabolism of 5-hydroxytryptamine in rat brain.
    SHARMAN DF; SMITH SE
    J Neurochem; 1962; 9():403-6. PubMed ID: 13911386
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.